LI-RADS 2018版在钆塞酸二钠增强MRI上诊断小于1.0 cm肝细胞癌的改良研究
本研究回顾性分析2016年1月至2020年12月间在MRI前1个月内接受钆塞酸二钠增强MRI检查、存在小于2.0 cm局灶性实性结节的患者,比较小于1.0 cm与1.0-1.9 cm肝细胞癌的主要和辅助征象,发现扩散受限是诊断小于1.0 cm肝细胞癌的唯一显著独立辅助征象(校正比值比=11.50,p<.001),应用扩散受限的改良LI-RADS较2018版LI-RADS显著提高诊断敏感度(61.8% vs. 53.5%,p<.001),特异度相似(97.3% vs. 97.8%,p=.157)。
要点
- 小于1.0 cm肝细胞癌较1.0-1.9 cm者更少出现强化包膜(7.1% vs. 31.1%,p<.001)和阈值增长(0% vs. 8.3%,p=.007)。
- 扩散受限是诊断小于1.0 cm肝细胞癌的唯一显著独立辅助征象(校正比值比=11.50,p<.001)。
- 应用扩散受限的改良LI-RADS较2018版LI-RADS诊断肝细胞癌敏感度更高(61.8% vs. 53.5%,p<.001),特异度相似(97.3% vs. 97.8%,p=.157)。
核心结论
- 扩散受限是诊断小于1.0 cm肝细胞癌的唯一显著独立辅助征象,应用扩散受限的改良LI-RADS可提高小于1.0 cm肝细胞癌的诊断敏感度。
研究设计与样本
- 回顾性分析2016年1月至2020年12月间在MRI前1个月内接受钆塞酸二钠增强MRI检查、存在小于2.0 cm局灶性实性结节的患者。
- 共纳入796个结节,其中小于1.0 cm者248个,1.0-1.9 cm者548个。
- 采用卡方检验比较小于1.0 cm与1.0-1.9 cm肝细胞癌的主要和辅助征象,采用单因素和多因素logistic回归分析确定与小于1.0 cm肝细胞癌相关的显著辅助征象。
- 采用广义估计方程比较LI-RADS v2018与改良LI-RADS(应用显著辅助征象)诊断LR-5的敏感度和特异度。
关键影像表现/征象
- 小于1.0 cm肝细胞癌较1.0-1.9 cm者更少出现强化包膜(7.1% vs. 31.1%,p<.001)。
- 小于1.0 cm肝细胞癌较1.0-1.9 cm者更少出现阈值增长(0% vs. 8.3%,p=.007)。
诊断标准与关键数值
- 扩散受限是诊断小于1.0 cm肝细胞癌的唯一显著独立辅助征象(校正比值比=11.50,p<.001)。
- 改良LI-RADS(应用扩散受限)诊断肝细胞癌的敏感度为61.8%,LI-RADS v2018为53.5%(p<.001)。
- 改良LI-RADS(应用扩散受限)诊断肝细胞癌的特异度为97.3%,LI-RADS v2018为97.8%(p=.157)。
临床应用与阅片要点
- 在钆塞酸二钠增强MRI上评估小于1.0 cm的局灶性实性结节时,可将扩散受限作为辅助征象用于改良LI-RADS分类以提高诊断敏感度。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: We aimed to develop and evaluate a modified Liver Imaging Reporting and Data System (LI-RADS) version 2018 using significant ancillary features for diagnosing hepatocellular carcinoma (HCC) < 1.0 cm on gadoxetate disodium-enhanced magnetic resonance imaging (MRI).
METHODS: Patients who underwent preoperative gadoxetate disodium-enhanced MRI for focal solid nodules < 2.0 cm within 1 month of MRI between January 2016 and December 2020 were retrospectively analyzed. Major and ancillary features were compared between HCCs of < 1.0 cm and 1.0-1.9 cm using the chi-square test. Significant ancillary features associated with HCC < 1.0 cm were determined by univariable and multivariable logistic regression analysis. The sensitivity and specificity of LR-5 were compared between LI-RADS v2018 and our modified LI-RADS (applying the significant ancillary feature) using generalized estimating equations.
RESULTS: Of 796 included nodules, 248 were < 1.0 cm and 548 were 1.0-1.9 cm. HCC < 1.0 cm less frequently showed an enhancing capsule (7.1% vs. 31.1%, p < .001) and threshold growth (0% vs. 8.3%, p = .007) than HCC of 1.0-1.9 cm. Restricted diffusion was the only ancillary feature significant for diagnosing HCC < 1.0 cm (adjusted odds ratio = 11.50, p < .001). In the diagnosis of HCC, our modified LI-RADS using restricted diffusion had significantly higher sensitivity than LI-RADS v2018 (61.8% vs. 53.5%, p < .001), with similar specificity (97.3% vs. 97.8%, p = .157).
CONCLUSION: Restricted diffusion was the only significant independent ancillary feature for diagnosing HCC < 1.0 cm. Our modified LI-RADS using restricted diffusion can improve the sensitivity for HCC < 1.0 cm.
KEY POINTS: • The imaging features of hepatocellular carcinoma (HCC) < 1.0 cm differed from those of HCC of 1.0-1.9 cm. • Restricted diffusion was the only significant independent ancillary feature for HCC < 1.0 cm. • Modified Liver Imaging Reporting and Data System (LI-RADS) with the addition of restricted diffusion can improve the sensitivity for HCC < 1.0 cm.
引用
- Jang HJ, Choi SH, Choi SJ, et al. LI-RADS version 2018 for hepatocellular carcinoma < 1.0 cm on gadoxetate disodium-enhanced magnetic resonance imaging. Eur Radiol. 2023. PMID: 37017700. doi:10.1007/s00330-023-09554-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。